Eckert & Ziegler BEBIG, Mick Radio-Nuclear Instruments, WOLF-Medizintechnik (WOmed)

Press Releases

We are keeping you informed! If you have questions regarding our press releases, feel free to contact us via the website´s contact form. Stay up-to-date with our companies latest news:
 
Print

Eckert & Ziegler BEBIG : Changes to the Board of Directors. Capital increase by contribution in cash

Press Release

REGULATED INFORMATION

Eckert & Ziegler BEBIG: Changes to the Board of Directors - Prof. Dr. Lutz Uharek and Dr. Harald Hasselmann elected as new Board of Directors members. Capital increase by contribution in cash with cancellation of the preferential rights of the current shareholders, authorized capital  and reverse stock split

Seneffe, June 9, 2016. Eckert & Ziegler BEBIG SA has two new Board of Directors members. Prof. Dr. Lutz Uharek was elected to be a new member of the Board of Directors at today's Annual General Meeting in Seneffe (Belgium). The physician follows Martin Hölscher, whose time in office has ended after two terms in accordance with the Articles of Association. "We would like to thank Mr. Hölscher for the excellent and trustful working relationship and are pleased to have found in Professor Uharek a qualified successor with comprehensive medical expertise," said Dr. Andreas Eckert, Chairman of the Board of Directors of Eckert & Ziegler BEBIG SA

Prof. Uharek is a hematology oncologist and a chief resident at the Medical Department, Division of Hematology, Oncology and Tumor Immunology at the Charité Campus Virchow Klinikum in Berlin. As an expert in the field of stem cell transplantation and clinical cell therapy, and as the head of scientific working groups and a principal investigator in phase I and II studies, he has extensive expertise in translational research and the early clinical use of cellular immunotherapeutics.

The Annual General Meeting also elected Dr. Harald Hasselman, who has been with the company since October 2015, to the Board of Directors. He follows Dr. Edgar Löffler, who remains a Managing Director, but is leaving the Board of Directors at his own request. "Over the past eight years, Dr. Löffler has played an instrumental role in driving the focus toward being a complete provider of brachytherapy. We would like to thank him for this, and we are pleased that he will continue to support the company on its growth course in his role as member of the management committee," said Dr. Andreas Eckert, Chairman of the Board of Directors of Eckert & Ziegler BEBIG SA.

An Extraordinary General Meeting, that followed the Annual General Meeting, decided to increase its capital by way of a contribution in cash with cancellation of the preferential right of the current shareholders for an amount of EUR 5,056,168.48, of which EUR 3,560,771.10 EUR is allocated to the share capital and EUR 1,495,397.38 as share premium. The beneficiary of the cancellation of the preferential rights is the company under German law, Eckert & Ziegler EZAG AG, i.e. the controlling shareholder of the company.

In accordance with Article 598 of the Company Code, the board of directors decided that the issue price shall amount to EUR 0.88 per new share (i.e. the average trading price of the 30 last days) and as a result of the capital increase decided today, 5,745,646 new shares, without nominal value, were issued, as compensation for the above-mentioned contribution and the share capital of the company was increased to bring it from EUR 10,879,026.72 to EUR 14,439,797,82 EUR

The extraordinary general meeting of shareholders also decided to resolve on (i) a  reverse stock split with a ratio of ten (10) existing shares to one (1) share, with a delegation of powers granted to the board of directors to implement this reverse stock split and (ii) the renewal the authorisation granted to the board of directors to increase the share capital of the company (authorised capital).

About Eckert & Ziegler BEBIG

Contributing to saving lives!
Eckert & Ziegler BEBIG (Euronext: EZBG; Reuters: EZBG.BR; Bloomberg: EZBG:BB) is a European-based group active in the medical device segment of the health care industry. Its core business is the production and distribution of medical products for the treat­ment of cancer using brachytherapy. The company's headquarters are in Belgium, with production facilities in Germany and in the USA, as well as subsidiaries throughout Europe, the USA, India and Brazil. In addition, Eckert & Ziegler BEBIG has a worldwide network of distributors and agents to support the international marketing and distribution of its product line. The company's products and equipment are intended for use by oncologists, radiotherapists, urologists, ophthalmologists and medical physicists. Eckert & Ziegler BEBIG employs approximately 140 people. The company has been listed on the Euronext stock exchange since April 1997.

Contact:

Eckert & Ziegler BEBIG SA
Investor Relations
Tel.: +32 (0) 64 520 808
E-mail: ir@bebig.com

Back